Complications from stereotactic body radiotherapy for lung cancer

Cancers

Volumn 7, Issue 2, 2015, Pages 981-1004

  Kang, Kylie H ^a   Okoye, Christian C ^a   Patel, Ravi B ^a   Siva, Shankar ^b   Biswas, Tithi ^a   Ellis, Rodney J ^a   Yao, Min ^a   Machtay, Mitchell ^a   Lo, Simon S ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Complications; Non small cell lung cancer (NSCLC); Stereotactic ablative radiotherapy (SABR); Stereotactic body radiation therapy (SBRT); Toxicity

Indexed keywords

ATELECTASIS; BRONCHIAL NECROSIS; BRONCHUS STENOSIS; CHEST WALL PAIN; DOSIMETRY; ESOPHAGUS PERFORATION; HEMOPTYSIS; HUMAN; LUNG HEMORRHAGE; NON SMALL CELL LUNG CANCER; PATIENT SELECTION; PLEURAL FIBROSIS; RADIATION INDUCED BRACHIAL PLEXOPATHY; RADIATION INJURY; RADIATION PNEUMONIA; REVIEW; RIB FRACTURE; SIMULATION; SKIN TOXICITY; SPONTANEOUS PNEUMOTHORAX; STEREOTACTIC BODY RADIATION THERAPY; TRACHEOESOPHAGEAL FISTULA; TREATMENT PLANNING; VAGUS NERVE INJURY;

EID: 84935038274     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7020820     Document Type: Review

References (122)

1. Senan, S. Stereotactic body radiotherapy: Do central lung tumors still represent a “no-fly zone”? Onkologie 2012, 35, 406–407.
2. Haffty, B.G.; Goldberg, N.B.; Gerstley, J.; Fischer, D.B.; Peschel, R.E. Results of radical radiation therapy in clinical stage I, technically operable non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 1988, 15, 69–73.
3. Gauden, S.; Ramsay, J.; Tripcony, L. The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. Chest 1995, 108, 1278–1282.
4. Fang, L.C.; Komaki, R.; Allen, P.; Guerrero, T.; Mohan, R.; Cox, J.D. Comparison of outcomes for patients with medically inoperable stage I non-small-cell lung cancer treated with two-dimensional vs. Three-dimensional radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66, 108–116.
5. Rosenzweig, K.E.; Fox, J.L.; Yorke, E.; Amols, H.; Jackson, A.; Rusch, V.; Kris, M.G.; Ling, C.C.; Leibel, S.A. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer 2005, 103, 2118–2127.
6. Bradley, J.; Graham, M.V.; Winter, K.; Purdy, J.A.; Komaki, R.; Roa, W.H.; Ryu, J.K.; Bosch, W.; Emami, B. Toxicity and outcome results of rtog 9311: A phase I–II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61, 318–328.
7. Narayan, S.; Henning, G.T.; Ten Haken, R.K.; Sullivan, M.A.; Martel, M.K.; Hayman, J.A. Results following treatment to doses of 92.4 or 102.9 gy on a phase I dose escalation study for non-small cell lung cancer. Lung Cancer 2004, 44, 79–88.
8. Barriger, R.B.; Forquer, J.A.; Brabham, J.G.; Andolino, D.L.; Shapiro, R.H.; Henderson, M.A.; Johnstone, P.A.; Fakiris, A.J. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2012, 82, 457–462.
9. Timmerman, R.; Papiez, L.; McGarry, R.; Likes, L.; DesRosiers, C.; Frost, S.; Williams, M. Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003, 124, 1946–1955.
10. Timmerman, R.; McGarry, R.; Yiannoutsos, C.; Papiez, L.; Tudor, K.; DeLuca, J.; Ewing, M.; Abdulrahman, R.; DesRosiers, C.; Williams, M. et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J. Clin. Oncol. 2006, 24, 4833–4839.
11. Amini, A.; Yeh, N.; Gaspar, L.E.; Kavanagh, B.; Karam, S.D. Stereotactic body radiation therapy (sbrt) for lung cancer patients previously treated with conventional radiotherapy: A review. Radiat. Oncol. 2014, 9.
12. Zheng, X.; Schipper, M.; Kidwell, K.; Lin, J.; Reddy, R.; Ren, Y.; Chang, A.; Lv, F.; Orringer, M.; Spring Kong, F.M. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: A meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 2014, 90, 603–611.
13. Crabtree, T.D.; Denlinger, C.E.; Meyers, B.F.; El Naqa, I.; Zoole, J.; Krupnick, A.S.; Kreisel, D.; Patterson, G.A.; Bradley, J.D. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 2010, 140, 377–386.
14. Lo, S.S.; Fakiris, A.J.; Chang, E.L.; Mayr, N.A.; Wang, J.Z.; Papiez, L.; Teh, B.S.; McGarry, R.C.; Cardenes, H.R.; Timmerman, R.D. Stereotactic body radiation therapy: A novel treatment modality. Nat. Rev. Clin. Oncol. 2010, 7, 44–54.
15. Fakiris, A.J.; McGarry, R.C.; Yiannoutsos, C.T.; Papiez, L.; Williams, M.; Henderson, M.A.; Timmerman, R. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: Four-year results of a prospective phase ii study. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75, 677–682.
16. Song, S.Y.; Choi, W.; Shin, S.S.; Lee, S.W.; Ahn, S.D.; Kim, J.H.; Je, H.U.; Park, C.I.; Lee, J.S.; Choi, E.K. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer 2009, 66, 89–93.
17. Le, Q.-T.; Loo, B.W.; Ho, A.; Cotrutz, C.; Koong, A.C.; Wakelee, H.; Kee, S.T.; Constantinescu, D.; Whyte, R.I.; Donington, J. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J. Thorac. Oncol. 2006, 1, 802–809.
18. Kelsey, C.R.; Kahn, D.; Hollis, D.R.; Miller, K.L.; Zhou, S.M.; Clough, R.W.; Marks, L.B. Radiation-induced narrowing of the tracheobronchial tree: An in-depth analysis. Lung Cancer 2006, 52, 111–116.
19. Speiser, B.L.; Spratling, L. Radiation bronchitis and stenosis secondary to high dose rate endobronchial irradiation. Int. J. Radiat. Oncol. Biol. Phys. 1993, 25, 589–597.
20. Karlsson, K.; Nyman, J.; Baumann, P.; Wersall, P.; Drugge, N.; Gagliardi, G.; Johansson, K.A.; Persson, J.O.; Rutkowska, E.; Tullgren, O. et al. Retrospective cohort study of bronchial doses and radiation-induced atelectasis after stereotactic body radiation therapy of lung tumors located close to the bronchial tree. Int. J. Radiat. Oncol. Biol. Phys. 2013, 87, 590–595.
21. Rowe, B.P.; Boffa, D.J.; Wilson, L.D.; Kim, A.W.; Detterbeck, F.C.; Decker, R.H. Stereotactic body radiotherapy for central lung tumors. J. Thorac. Oncol. 2012, 7, 1394–1399.
22. Corradetti, M.N.; Haas, A.R.; Rengan, R. Central-airway necrosis after stereotactic body-radiation therapy. N. Engl. J. Med. 2012, 366, 2327–2329.
23. Wu, A.J.; Williams, E.; Modh, A.; Foster, A.; Yorke, E.; Rimner, A.; Jackson, A. Dosimetric predictors of esophageal toxicity after stereotactic body radiotherapy for central lung tumors. Radiother. Oncol. 2014, 112, 267–271.
24. Onimaru, R.; Shirato, H.; Shimizu, S.; Kitamura, K.; Xu, B.; Fukumoto, S.; Chang, T.C.; Fujita, K.; Oita, M.; Miyasaka, K. et al. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int. J. Radiat. Oncol. Biol. Phys. 2003, 56, 126–135.
25. Palma, D.A.; Senan, S.; Oberije, C.; Belderbos, J.; de Dios, N.R.; Bradley, J.D.; Barriger, R.B.; Moreno-Jimenez, M.; Kim, T.H.; Ramella, S. et al. Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: An individual patient data meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 2013, 87, 690–696.
26. Gomez, D.R.; Hunt, M.A.; Jackson, A.; O’Meara, W.P.; Bukanova, E.N.; Zelefsky, M.J.; Yamada, Y.; Rosenzweig, K.E. Low rate of thoracic toxicity in palliative paraspinal single-fraction stereotactic body radiation therapy. Radiother. Oncol. 2009, 93, 414–418.
27. Timmerman, R.D. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin. Radiat. Oncol. 2008, 18, 215–222.
28. Abelson, J.A.; Murphy, J.D.; Loo, B.W., Jr.; Chang, D.T.; Daly, M.E.; Wiegner, E.A.; Hancock, S.; Chang, S.D.; Le, Q.T.; Soltys, S.G. et al. Esophageal tolerance to high-dose stereotactic ablative radiotherapy. Dis. Esophagus 2012, 25, 623–629.
29. Werner-Wasik, M.; Pequignot, E.; Leeper, D.; Hauck, W.; Curran, W. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: A multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48, 689–696.
30. Scappaticci, F.A.; Fehrenbacher, L.; Cartwright, T.; Hainsworth, J.D.; Heim, W.; Berlin, J.; Kabbinavar, F.; Novotny, W.; Sarkar, S.; Hurwitz, H. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J. Surg Oncol. 2005, 91, 173–180.
31. Goodgame, B.; Veeramachaneni, N.; Patterson, A.; Govindan, R. Tracheo-esophageal fistula with bevacizumab after mediastinal radiation. J. Thorac. Oncol. 2008, 3, 1080–1081.
32. NCT02319889: Pilot Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma. Available online: https://clinicaltrials.gov/ct2/show/NCT02319889 (accessed on 3 January 2015).
33. Evans, J.; Gomez, D.; Amini, A.; Rebueno, N.; Allen, P.; Martel, M.; Rineer, J.; Ang, K.; McAvoy, S.; Cox, J.; et al. Aortic dose constraints when reirradiating thoracic tumors. Radiother. Oncol. 2013, 106, 327–332.
34. Shultz, D.B.; Trakul, N.; Maxim, P.G.; Diehn, M.; Loo, B.W., Jr. Vagal and recurrent laryngeal neuropathy following stereotactic ablative radiation therapy in the chest. Pract. Radiat.Oncol. 2014, 4, 272–278.
35. Forquer, J.A.; Fakiris, A.J.; Timmerman, R.D.; Lo, S.S.; Perkins, S.M.; McGarry, R.C.; Johnstone, P.A. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: Dose-limiting toxicity in apical tumor sites. Radiother. Oncol. 2009, 93, 408–413.
36. Ito, M.; Niho, S.; Nihei, K.; Yoh, K.; Ohmatsu, H.; Ohe, Y. Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy. BMC Cancer 2012, 12.
37. Kim, Y.-H.; Kim, E.-Y.; Ban, H.-J.; Oh, I.-J.; Kim, K.-S.; Kim, Y.-C.; Ahn, S.-J. Risk factors for fatal hemoptysis after concurrent chemoradiation therapy in patients with non-small cell lung carcinoma. Chonnam Med. J. 2010, 46, 19–24.
38. Reck, M.; Barlesi, F.; Crino, L.; Henschke, C.I.; Isla, D.; Stiebeler, S.; Spigel, D.R. Predicting and managing the risk of pulmonary haemorrhage in patients with nsclc treated with bevacizumab: A consensus report from a panel of experts. Ann. Oncol. 2012, 23, 1111–1120.
39. Chi, A.; Nguyen, N.P.; Komaki, R. The potential role of respiratory motion management and image guidance in the reduction of severe toxicities following stereotactic ablative radiation therapy for patients with centrally located early stage non-small cell lung cancer or lung metastases. Front. Oncol. 2014, 4.
40. Milano, M.T.; Chen, Y.; Katz, A.W.; Philip, A.; Schell, M.C.; Okunieff, P. Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy. Radiother. Oncol. 2009, 91, 301–306.
41. Oshiro, Y.; Aruga, T.; Tsuboi, K.; Marino, K.; Hara, R.; Sanayama, Y.; Itami, J. Stereotactic body radiotherapy for lung tumors at the pulmonary hilum. Strahlenther. Onkol. 2010, 186, 274–279.
42. Ohnishi, K.; Shioyama, Y.; Nomoto, S.; Sasaki, T.; Ohga, S.; Yoshitake, T.; Toba, T.; Atsumi, K.; Shiinoki, T.; Terashima, H. et al. Spontaneous pneumothorax after stereotactic radiotherapy for non-small-cell lung cancer. Jpn. J. Radiol. 2009, 27, 269–274.
43. Pezner, R.D.; Horak, D.A.; Sayegh, H.O.; Lipsett, J.A. Spontaneous pneumothorax in patients irradiated for hodgkin’s disease and other malignant lymphomas. Int. J. Radiat. Oncol. Biol. Phys. 1990, 18, 193–198.
44. Stephans, K.L.; Djemil, T.; Reddy, C.A.; Gajdos, S.M.; Kolar, M.; Machuzak, M.; Mazzone, P.; Videtic, G.M.M. Comprehensive analysis of pulmonary function test (pft) changes after stereotactic body radiotherapy (sbrt) for stage I lung cancer in medically inoperable patients. J. Thorac. Oncol. 2009, 4, 838–844.
45. Henderson, M.; McGarry, R.; Yiannoutsos, C.; Fakiris, A.; Hoopes, D.; Williams, M.; Timmerman, R. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage i non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72, 404–409.
46. Guckenberger, M.; Kestin, L.L.; Hope, A.J.; Belderbos, J.; Werner-Wasik, M.; Yan, D.; Sonke, J.-J.; Bissonnette, J.P.; Wilbert, J.; Xiao, Y. et al. Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer? J. Thorac. Oncol. 2012, 7, 542–551.
47. Ohashi, T.; Takeda, A.; Shigematsu, N.; Kunieda, E.; Ishizaka, A.; Fukada, J.; Deloar, H.M.; Kawaguchi, O.; Takeda, T.; Takemasa, K. et al. Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62, 1003–1008.
48. Takeda, A.; Enomoto, T.; Sanuki, N.; Handa, H.; Aoki, Y.; Oku, Y.; Kunieda, E. Reassessment of declines in pulmonary function ≥1 year after stereotactic body radiotherapy. Chest 2013, 143, 130–137.
49. Stanic, S.; Paulus, R.; Timmerman, R.D.; Michalski, J.; Barriger, R.B.; Bezjak, A.; Videtic, G.M.; Bradley, J. No clinically significant changes in pulmonary function following stereotactic body radiation therapy (sbrt) among medically inoperable patients with early stage peripheral non-small cell lung cancer: An analysis of RTOG 0236. Int. J. Radiat. Oncol. Biol. Phys. 2012, 84.
50. Seppenwoolde, Y.; de Jaeger, K.; Boersma, L.J.; Belderbos, J.S.A.; Lebesque, J.V. Regional differences in lung radiosensitivity after radiotherapy for non–small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2004, 60, 748–758.
51. Tucker, S.L.; Jin, H.; Wei, X.; Wang, S.; Martel, M.K.; Komaki, R.; Liu, H.H.; Mohan, R.; Chen, Y.; Cox, J.D. et al. Impact of toxicity grade and scoring system on the relationship between mean lung dose and risk of radiation pneumonitis in a large cohort of patients with non–small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010, 77, 691–698.
52. Nagata, Y.; Takayama, K.; Matsuo, Y.; Norihisa, Y.; Mizowaki, T.; Sakamoto, T.; Sakamoto, M.; Mitsumori, M.; Shibuya, K.; Araki, N. et al. Clinical outcomes of a phase I/II study of 48 gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63, 1427–1431.
53. Yamashita, H.; Nakagawa, K.; Nakamura, N.; Koyanagi, H.; Tago, M.; Igaki, H.; Shiraishi, K.; Sasano, N.; Ohtomo, K. Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat. Oncol. 2007, 2.
54. Guckenberger, M.; Heilman, K.; Wulf, J.; Mueller, G.; Beckmann, G.; Flentje, M. Pulmonary injury and tumor response after stereotactic body radiotherapy (sbrt): Results of a serial follow-up ct study. Radiother. Oncol. 2007, 85, 435–442.
55. Zimmermann, F.B.; Geinitz, H.; Schill, S.; Thamm, R.; Nieder, C.; Schratzenstaller, U.; Molls, M. Stereotactic hypofractionated radiotherapy in stage I (t1-2 n0 m0) non-small-cell lung cancer (nsclc). Acta Oncol. 2006, 45, 796–801.
56. Guckenberger, M.; Baier, K.; Polat, B.; Richter, A.; Krieger, T.; Wilbert, J.; Mueller, G.; Flentje, M. Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiother. Oncol. 2010, 97, 65–70.
57. Lo, S.S.; Sahgal, A.; Chang, E.L.; Mayr, N.A.; Teh, B.S.; Huang, Z.; Schefter, T.E.; Yao, M.; Machtay, M.; Slotman, B.J. et al. Serious complications associated with stereotactic ablative radiotherapy and strategies to mitigate the risk. Clin. Oncol. (R. Coll. Radiol.) 2013, 25, 378–387.
58. Borst, G.R.; Ishikawa, M.; Nijkamp, J.; Hauptmann, M.; Shirato, H.; Onimaru, R.; van den Heuvel, M.M.; Belderbos, J.; Lebesque, J.V.; Sonke, J.J. Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. Radiother. Oncol. 2009, 91, 307–313.
59. Ong, C.L.; Palma, D.; Verbakel, W.F.; Slotman, B.J.; Senan, S. Treatment of large stage I–II lung tumors using stereotactic body radiotherapy (SBRT): Planning considerations and early toxicity. Radiother. Oncol. 2010, 97, 431–436.
60. Kyas, I.; Hof, H.; Debus, J.; Schlegel, W.; Karger, C.P. Prediction of radiation-induced changes in the lung after stereotactic body radiation therapy of non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007, 67, 768–774.
61. Hope, A.J.; Lindsay, P.E.; El Naqa, I.; Alaly, J.R.; Vicic, M.; Bradley, J.D.; Deasy, J.O. Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int. J. Radiat. Oncol. Biol. Phys. 2006, 65, 112–124.
62. Yorke, E.D.; Jackson, A.; Rosenzweig, K.E.; Merrick, S.A.; Gabrys, D.; Venkatraman, E.S.; Burman, C.M.; Leibel, S.A.; Ling, C.C. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54, 329–339.
63. Tucker, S.L.; Liao, Z.X.; Travis, E.L. Estimation of the spatial distribution of target cells for radiation pneumonitis in mouse lung. Int. J. Radiat. Oncol. Biol. Phys. 1997, 38, 1055–1066.
64. West, J.B. Respiratory Physiology: The Essentials; Wolters Kluwer Health/Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2012.
65. Matsuo, Y.; Shibuya, K.; Nakamura, M.; Narabayashi, M.; Sakanaka, K.; Ueki, N.; Miyagi, K.; Norihisa, Y.; Mizowaki, T.; Nagata, Y. et al. Dose-volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012, 83, e545–e549.
66. Yamashita, H.; Kobayashi-Shibata, S.; Terahara, A.; Okuma, K.; Haga, A.; Wakui, R.; Ohtomo, K.; Nakagawa, K. Prescreening based on the presence of ct-scan abnormalities and biomarkers (kl-6 and sp-d) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat. Oncol. 2010, 5.
67. Iwata, H.; Shibamoto, Y.; Baba, F.; Sugie, C.; Ogino, H.; Murata, R.; Yanagi, T.; Otsuka, S.; Kosaki, K.; Murai, T. et al. Correlation between the serum kl-6 level and the grade of radiation pneumonitis after stereotactic body radiotherapy for stage i lung cancer or small lung metastasis. Radiother. Oncol. 2011, 101, 267–270.
68. Kong, F.M.; Ao, X.; Wang, L.; Lawrence, T.S. The use of blood biomarkers to predict radiation lung toxicity: A potential strategy to individualize thoracic radiation therapy. Cancer Control. 2008, 15, 140–150.
69. Hara, R.; Itami, J.; Komiyama, T.; Katoh, D.; Kondo, T. Serum levels of kl-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors. Chest 2004, 125, 340–344.
70. Takeda, A.; Ohashi, T.; Kunieda, E.; Enomoto, T.; Sanuki, N.; Takeda, T.; Shigematsu, N. Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (sbrt) in patients with lung tumors. Int. J. Radiat. Oncol. Biol. Phys. 2010, 77, 685–690.
71. Yamaguchi, S.; Ohguri, T.; Ide, S.; Aoki, T.; Imada, H.; Yahara, K.; Narisada, H.; Korogi, Y. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: The potential risk of extensive radiation pneumonitis. Lung Cancer 2013, 82, 260–265.
72. Palma, D.; Lagerwaard, F.; Rodrigues, G.; Haasbeek, C.; Senan, S. Curative treatment of stage I non-small-cell lung cancer in patients with severe copd: Stereotactic radiotherapy outcomes and systematic review. Int. J. Radiat. Oncol. Biol. Phys. 2012, 82, 1149–1156.
73. Kimura, T.; Matsuura, K.; Murakami, Y.; Hashimoto, Y.; Kenjo, M.; Kaneyasu, Y.; Wadasaki, K.; Hirokawa, Y.; Ito, K.; Okawa, M. Ct appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: Are patients with pulmonary emphysema also candidates for sbrt for lung cancers? Int. J. Radiat. Oncol. Biol. Phys. 2006, 66, 483–491.
74. Jin, H.; Tucker, S.L.; Liu, H.H.; Wei, X.; Yom, S.S.; Wang, S.; Komaki, R.; Chen, Y.; Martel, M.K.; Mohan, R.; et al. Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy. Radiother. Oncol. 2009, 91, 427–432.
75. Takeda, A.; Kunieda, E.; Ohashi, T.; Aoki, Y.; Oku, Y.; Enomoto, T.; Nomura, K.; Sugiura, M. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. Chest 2012, 141, 858–866.
76. Bjermer, L.; Cai, Y.; Nilsson, K.; Hellstrom, S.; Henriksson, R. Tobacco smoke exposure suppresses radiation-induced inflammation in the lung: A study of bronchoalveolar lavage and ultrastructural morphology in the rat. Eur. Respir. J. 1993, 6, 1173–1180.
77. Bhattathiri, V.N. Possible role of plasma GSH in modulating smoking related radiation pneumonitis. Radiother. Oncol. 1999, 51, 291–292.
78. Takeda, A.; Ohashi, T.; Kunieda, E.; Sanuki, N.; Enomoto, T.; Takeda, T.; Oku, Y.; Shigematsu, N. Comparison of clinical, tumour-related and dosimetric factors in grade 0–1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours. Br. J. Radiol. 2012, 85, 636–642.
79. Stephans, K.L.; Djemil, T.; Reddy, C.A.; Gajdos, S.M.; Kolar, M.; Mason, D.; Murthy, S.; Rice, T.W.; Mazzone, P.; Machuzak, M. et al. A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: The cleveland clinic experience. J. Thorac. Oncol. 2009, 4, 976–982.
80. Andolino, D.L.; Forquer, J.A.; Henderson, M.A.; Barriger, R.B.; Shapiro, R.H.; Brabham, J.G.; Johnstone, P.A.; Cardenes, H.R.; Fakiris, A.J. Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver. Int. J. Radiat. Oncol. Biol. Phys. 2011, 80, 692–697.
81. Stephans, K.L.; Djemil, T.; Tendulkar, R.D.; Robinson, C.G.; Reddy, C.A.; Videtic, G.M. Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT). Int. J. Radiat. Oncol. Biol. Phys. 2012, 82, 974–980.
82. Welsh, J.; Thomas, J.; Shah, D.; Allen, P.K.; Wei, X.; Mitchell, K.; Gao, S.; Balter, P.; Komaki, R.; Chang, J.Y. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2011, 81, 91–96.
83. Voroney, J.P.; Hope, A.; Dahele, M.R.; Purdie, T.G.; Franks, K.N.; Pearson, S.; Cho, J.B.; Sun, A.; Payne, D.G.; Bissonnette, J.P. et al. Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer. J. Thorac. Oncol. 2009, 4, 1035–1037.
84. Mutter, R.W.; Liu, F.; Abreu, A.; Yorke, E.; Jackson, A.; Rosenzweig, K.E. Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012, 82, 1783–1790.
85. Fajardo, L.F.; Berthrong, M.; Anderson, R.E. Musculoskeletal system. In Radiation Pathology; Oxford University Press: New York, NY, USA, 2001; pp. 365–377.
86. Bongers, E.M.; Haasbeek, C.J.; Lagerwaard, F.J.; Slotman, B.J.; Senan, S. Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer. J. Thorac. Oncol. 2011, 6, 2052–2057.
87. Creach, K.M.; El Naqa, I.; Bradley, J.D.; Olsen, J.R.; Parikh, P.J.; Drzymala, R.E.; Bloch, C.; Robinson, C.G. Dosimetric predictors of chest wall pain after lung stereotactic body radiotherapy. Radiother. Oncol. 2012, 104, 23–27.
88. Pettersson, N.; Nyman, J.; Johansson, K.A. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: A dose- and volume-response analysis. Radiother. Oncol. 2009, 91, 360–368.
89. Dunlap, N.E.; Cai, J.; Biedermann, G.B.; Yang, W.; Benedict, S.H.; Sheng, K.; Schefter, T.E.; Kavanagh, B.D.; Larner, J.M. Chest wall volume receiving >30 gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2010, 76, 796–801.
90. Li, Q.; Swanick, C.W.; Allen, P.K.; Gomez, D.R.; Welsh, J.W.; Liao, Z.; Balter, P.A.; Chang, J.Y. Stereotactic ablative radiotherapy (SABR) using 70 gy in 10 fractions for non-small cell lung cancer: Exploration of clinical indications. Radiother. Oncol. 2014, 112, 256–261.
91. Radiation Therapy Oncology Group. RTOG 0813: Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients. Available online: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0813 (accessed on 3 January 2015).
92. Hoppe, B.S.; Laser, B.; Kowalski, A.V.; Fontenla, S.C.; Pena-Greenberg, E.; Yorke, E.D.; Lovelock, D.M.; Hunt, M.A.; Rosenzweig, K.E. Acute skin toxicity following stereotactic body radiation therapy for stage i non-small-cell lung cancer: Who’s at risk? Int. J. Radiat. Oncol. Biol. Phys. 2008, 72, 1283–1286.
93. Schierle, C.; Winograd, J.M. Radiation-induced brachial plexopathy: Review. Complication without a cure. J. Reconstr. Microsurg. 2004, 20, 149–152.
94. Ferrante, M.A. Brachial plexopathies: Classification, causes, and consequences. Muscle Nerve 2004, 30, 547–568.
95. Amini, A.; Yang, J.; Williamson, R.; McBurney, M.L.; Erasmus, J., Jr.; Allen, P.K.; Karhade, M.; Komaki, R.; Liao, Z.; Gomez, D. et al. Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012, 82, e391–e398.
96. Kori, S.H.; Foley, K.M.; Posner, J.B. Brachial plexus lesions in patients with cancer: 100 cases. Neurology 1981, 31, 45–50.
97. Chang, J.Y.; Li, Q.Q.; Xu, Q.Y.; Allen, P.K.; Rebueno, N.; Gomez, D.R.; Balter, P.; Komaki, R.; Mehran, R.; Swisher, S.G. et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: How to fly in a “no fly zone”. Int. J. Radiat. Oncol. Biol. Phys. 2014, 88, 1120–1128.
98. Lo, S.S.; Fakiris, A.J.; Wang, J.Z.; Mayr, N.A. In regard to Hoppe et al. (Int. J Radiat. Oncol. Biol. Phys. 2008;72:1283–1286). Int. J. Radiat. Oncol. Biol. Phys. 2009, 74, 977.
99. Wang, X.; Zhong, R.; Bai, S.; Xu, Q.; Zhao, Y.; Wang, J.; Jiang, X.; Shen, Y.; Xu, F.; Wei, Y. Lung tumor reproducibility with active breath control (ABC) in image-guided radiotherapy based on cone-beam computed tomography with two registration methods. Radiother. Oncol. 2011, 99, 148–154.
100. Guckenberger, M.; Kavanagh, A.; Webb, S.; Brada, M. A novel respiratory motion compensation strategy combining gated beam delivery and mean target position concept—A compromise between small safety margins and long duty cycles. Radiother. Oncol. 2011, 98, 317–322.
101. Taremi, M.; Hope, A.; Dahele, M.; Pearson, S.; Fung, S.; Purdie, T.; Brade, A.; Cho, J.; Sun, A.; Bissonnette, J.P. et al. Stereotactic body radiotherapy for medically inoperable lung cancer: Prospective, single-center study of 108 consecutive patients. Int. J. Radiat. Oncol. Biol. Phys. 2012, 82, 967–973.
102. Onishi, H.; Araki, T.; Shirato, H.; Nagata, Y.; Hiraoka, M.; Gomi, K.; Yamashita, T.; Niibe, Y.; Karasawa, K.; Hayakawa, K.; et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: Clinical outcomes in 245 subjects in a japanese multiinstitutional study. Cancer 2004, 101, 1623–1631.
103. Chang, J.Y.; Balter, P.A.; Dong, L.; Yang, Q.; Liao, Z.; Jeter, M.; Bucci, M.K.; McAleer, M.F.; Mehran, R.J.; Roth, J.A. et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72, 967–971.
104. Nuyttens, J.J.; Van Der Voort van Zyp, N.C.; Praag, J.; Aluwini, S.; van Klaveren, R.J.; Verhoef, C.; Pattynama, P.M.; Hoogeman, M.S. Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors. Radiother. Oncol. 2012, 102, 383–387.
105. Lagerwaard, F.J.; Haasbeek, C.J.; Smit, E.F.; Slotman, B.J.; Senan, S. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008, 70, 685–692.
106. Onishi, H.; Shirato, H.; Nagata, Y.; Hiraoka, M.; Fujino, M.; Gomi, K.; Niibe, Y.; Karasawa, K.; Hayakawa, K.; Takai, Y. et al. Hypofractionated stereotactic radiotherapy (hypofxsrt) for stage I non-small cell lung cancer: Updated results of 257 patients in a japanese multi-institutional study. J. Thorac. Oncol. 2007, 2, S94–S100.
107. Uematsu, M.; Shioda, A.; Suda, A.; Fukui, T.; Ozeki, Y.; Hama, Y.; Wong, J.R.; Kusano, S. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: A 5-year experience. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51, 666–670.
108. Senan, S.; Haasbeek, N.J.; Smit, E.F.; Lagerwaard, F.J. Stereotactic radiotherapy for centrally located early-stage lung tumors. J. Clin. Oncol. 2007, 25, 464.
109. Olsen, J.R.; Robinson, C.G.; El Naqa, I.; Creach, K.M.; Drzymala, R.E.; Bloch, C.; Parikh, P.J.; Bradley, J.D. Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2011, 81, e299–e303.
110. Haasbeek, C.J.; Lagerwaard, F.J.; Slotman, B.J.; Senan, S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J. Thorac. Oncol. 2011, 6, 2036–2043.
111. Guckenberger, M.; Wulf, J.; Mueller, G.; Krieger, T.; Baier, K.; Gabor, M.; Richter, A.; Wilbert, J.; Flentje, M. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: Relevance of 4d dose calculation. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74, 47–54.
112. Radiation Therapy Oncology Group. RTOG 0915: A Randomized Phase ii Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients with Stage I Peripheral Non-Small Cell Lung Cancer. Available online: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0915 (accessed on 3 January 2015).
113. Radiation Therapy Oncology Group. RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I/II Non-Small Cell Lung Cancer. Available online: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0236 (accessed on 3 January 2015).
114. Nagata, Y.; Wulf, J.; Lax, I.; Timmerman, R.; Zimmermann, F.; Stojkovski, I.; Jeremic, B. Stereotactic radiotherapy of primary lung cancer and other targets: Results of consultant meeting of the international atomic energy agency. Int. J. Radiat. Oncol. Biol. Phys. 2011, 79, 660–669.
115. Verbakel, W.F.; Senan, S.; Cuijpers, J.P.; Slotman, B.J.; Lagerwaard, F.J. Rapid delivery of stereotactic radiotherapy for peripheral lung tumors using volumetric intensity-modulated arcs. Radiother. Oncol. 2009, 93, 122–124.
116. Yang, J.; Fowler, J.F.; Lamond, J.P.; Lanciano, R.; Feng, J.; Brady, L.W. Red shell: Defining a high-risk zone of normal tissue damage in stereotactic body radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2010, 77, 903–909.
117. Dong, P.; Lee, P.; Ruan, D.; Long, T.; Romeijn, E.; Low, D.A.; Kupelian, P.; Abraham, J.; Yang, Y.; Sheng, K. 4pi noncoplanar stereotactic body radiation therapy for centrally located or larger lung tumors. Int. J. Radiat. Oncol. Biol. Phys. 2013, 86, 407–413.
118. Prevost, J.B.; Voet, P.; Hoogeman, M.; Praag, J.; Levendag, P.; Nuyttens, J.J. Four-dimensional stereotactic radiotherapy for early stage non-small cell lung cancer: A comparative planning study. Technol. Cancer Res. Treat. 2008, 7, 27–33.
119. Chi, A.; Ma, P.; Fu, G.; Hobbs, G.; Welsh, J.S.; Nguyen, N.P.; Jang, S.Y.; Dai, J.; Jin, J.; Komaki, R. Critical structure sparing in stereotactic ablative radiotherapy for central lung lesions: Helical tomotherapy vs. Volumetric modulated arc therapy. PLoS ONE 2013, 8, e59729.
120. Prendergast, B.M.; Dobelbower, M.C.; Bonner, J.A.; Popple, R.A.; Baden, C.J.; Minnich, D.J.; Cerfolio, R.J.; Spencer, S.A.; Fiveash, J.B. Stereotactic body radiation therapy (SBRT) for lung malignancies: Preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minute. Radiat. Oncol. 2013, 8.
121. Kragl, G.; Baier, F.; Lutz, S.; Albrich, D.; Dalaryd, M.; Kroupa, B.; Wiezorek, T.; Knoos, T.; Georg, D. Flattening filter free beams in sbrt and imrt: Dosimetric assessment of peripheral doses. Z. Med. Phys. 2011, 21, 91–101.
122. Trakul, N.; Chang, C.N.; Harris, J.; Chapman, C.; Rao, A.; Shen, J.; Quinlan-Davidson, S.; Filion, E.J.; Wakelee, H.A.; Colevas, A.D. et al. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. Int. J. Radiat. Oncol. Biol. Phys. 2012, 84, 231–237.